Mitochondrial pharmacogenomics: barcode for antibiotic therapy.

Area of Science:

• Mitochondrial biology
• Pharmacology
• Genetics

Background:

• Ribosomal RNA (rRNA)-targeting drugs are effective antibiotics that inhibit bacterial protein synthesis.
• Mitochondria share bacterial origins, possessing similar protein synthesis machinery, including ribosomal RNA.
• Mitochondrial rRNAs exhibit a higher mutation rate compared to nuclear rRNAs.

Purpose of the Study:

• To explore the implications of mitochondrial rRNA mutations on antibiotic susceptibility.
• To investigate the potential for antibiotic-induced mitochondrial toxicity.
• To highlight the feasibility of a pharmacogenomic approach for antibiotic therapy.

Main Methods:

• Analysis of interactions between antibiotics and mitochondrial DNA (mtDNA) genetic variants.
• Comparative analysis of bacterial and mitochondrial rRNA structures.
• Assessment of mitochondrial function and toxicity in the presence of specific mutations and antibiotics.

Main Results:

• Certain mitochondrial rRNA mutations can mimic bacterial rRNA structures, increasing susceptibility to rRNA-targeting antibiotics.
• Antibiotic exposure in individuals with specific mitochondrial mutations can lead to impaired mitochondrial function.
• These interactions can result in observable toxic effects.

Conclusions:

• Mitochondrial rRNA mutations pose a risk for antibiotic-induced toxicity.
• Pharmacogenomic systems can analyze antibiotic-mtDNA variant interactions.
• A pharmacogenomic approach is viable for tailoring antibiotic therapy to individual genetic profiles, mitigating mitochondrial side effects.